Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

Buster, Erik H.C.J.; Flink, Hajo J.; Çakalǒglu, Yılmaz; Simon, Krzysztof; Trojan, Jörg; Tabak, Fehmı; So, Thomas M K; Feinman, S.V.; Mach, Tomasz; Akarca, Ulus Salih; Schutten, Martin; Tielemans, Wanda; Vuuren, Anneke J. van; Hansen, Bettina E.; Janssen, Harry L.A.

doi:10.1053/j.gastro.2008.05.031

Cited by 366 publications

(345 citation statements)

References 26 publications

Supporting

Mentioning

326

Contrasting

Unclassified

Order By: Relevance

“…16 ers (loss of HBeAg 6 months postreatment) remained HBeAg-negative, whereas 58% of the initial responders presented levels of HBV-DNA < 2,000 UI/mL, three years after treatment. 30 Similarly, in a study conducted in Hong Kong, 46% of the initial responders remained HBeAg-negative and 29% presented levels of HBV-DNA < 5,000 UI/mL, three years after treatment. 15 The sustained disappearance of HBsAg is a more complete marker for viral suppression compared to the disappearance of HBeAg.…”

Section: Sustained Response Versus Maintained Responsementioning

confidence: 93%

“…8,[31][32][33][34][35] Among patients who received a one-year treatment with PEG-IFN, 9%-11% lost HBsAg three years after the end of treatment. 24,30 Therefore, predictors for disappearance of HBsAg during treatment are more important than those for seroconversion, but a longer-term follow-up is necessary for their assessment.…”

Section: Sustained Response Versus Maintained Responsementioning

confidence: 99%

See 1 more Smart Citation

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Ferreira

Tenore

2010

Braz J Infect Dis

View full text Add to dashboard Cite

The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment response of this disease have been studied, both before and during the course of medication. Therapy stopping rules have been proposed, which may be useful in patients presenting poor treatment tolerance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotyp

show abstract

Section: Sustained Response Versus Maintained Responsementioning

confidence: 93%

Section: Sustained Response Versus Maintained Responsementioning

confidence: 99%

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Ferreira

Tenore

2010

Braz J Infect Dis

View full text Add to dashboard Cite

show abstract

“…Moreover, HBsAg loss occurs rarely with a yearly rate of 1-3% [8]. Alternatively, a 1-year course of peginterferon-a (PEG-IFN) therapy induces a higher rate of HBeAg seroconversion (30%), a potential for the development of SVR (20-30%), and a high yearly rate of HBsAg in SVRs (10-15%) [20][21][22][23][24].…”

Section: Quantitative Hbsag In Peginterferon and Nucleos(t)ide Analog Tmentioning

confidence: 99%

Chronic hepatitis B: back to the future with HBsAg

Moucari

Lada

Marcellin³

2009

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

“…The durable effect after stopping (peg)interferon administration is one specific advantage of this therapy. In another report [31] , 81% of HBeAg-positive patients who achieved HBeAg-negative conversion by peginterferon-alpha-2b sustained their effect at years 3 after stopping interferon administration, and 27% of patients who could not achieve HBeAg-negative conversion at week 26 achieved HBeAg-negative conversion at years 3 ( Table 2) [31] . In that report [31] , 11% of all patients and 30% of patients who achieved HBeAg-negative conversion at month 6 achieved HBsAg-negative conversion even though 31% of all patients in this trial were genotype A and 47% were given additional NUCs.…”

Section: Peginterferon Therapymentioning

confidence: 99%

“…Its administration is performed only once per week. There have been several reports about peginterferon for HBeAg-positive or HBeAgnegative patients (Tables 1-3) [27][28][29][30][31][32][33][34][35] . In the comparison trial with standard interferon-alpha and peginterferonalpha in Asia, the combined responses, defined as HBeAg loss, HBV DNA suppression (< 500000 copies/mL) and ALT normalization, were 28% vs 12%, respectively (P = 0.036), and the superiority of peginterferon-alpha to standard interferon has been demonstrated [27] .…”

Section: Peginterferon Therapymentioning

confidence: 99%

Current and future directions for treating hepatitis B virus infection

Tawada

Yokosuka

2015

WJH

View full text Add to dashboard Cite

Hepatitis B virus (HBV) persistently infects approximately 350 million people, and approximately 600000 liverrelated deaths are observed per year worldwide. HBV infection is also one of the major risk factors for hepatocellular carcinoma (HCC). The persistence of serum hepatitis B e antigen (HBeAg) and high level of serum HBV DNA are thought to reflect a high HBV replication status in hepatocytes, causing cirrhosis, HCC and liver-related deaths. It has been reported that antiviral therapy, such as peginterferon and nucleos(t)ide analogues (NUCs), could suppress liver-related death by inhibiting the HBV DNA levels and inducing seroconversion from HBeAg to antibody to HBe antigen. Currently, peginterferon is widely used, but there are also several disadvantages in the use of peginterferon, such as various adverse events, the administration route and duration. It is difficult to predict the effects of treatment and interferon is contraindicated for the patients with advanced fibrosis of the liver and cirrhosis. With respect to NUCs, entecavir and tenofovir disoproxil fumarate are current the first-choice drugs. NUCs can be administered orally, and their anti-viral effects are stronger than that of peginterferon. However, because cessation of NUC administration leads to high levels of viral replication and causes severe hepatitis, they must be administered for a long time. On the other hand, the use of both interferon and NUCs cannot eliminate covalently closed circular DNA of HBV. In this review, we evaluate the natural course of chronic HBV infection and then provide an outline of these representative drugs, such as peginterferon, entecavir and tenofovir disoproxil fumarate.

show abstract

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

Cited by 366 publications

References 26 publications

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Chronic hepatitis B: back to the future with HBsAg

Current and future directions for treating hepatitis B virus infection

Contact Info

Product

Resources

About